euro adhoc: LION bioscience AG / Mergers - Acquisitions - Takeovers / Ad-hoc release LION bioscience confirms take-over bid of Hopp family (DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

05.07.2006

Heidelberg, July 5, 2006 - LION bioscience received today the
information that two investment-companies of the Hopp family,
DH-Capital GmbH & Co. KG und OH Beteiligungen GmbH & Co. KG, will
make a voluntary bid to acquire all shares of LION bioscience AG at
a price of EUR 1.82 per share.

This decision is to be seen before the background of the contract
signed by LION bioscience AG today to acquire SYGNIS Bioscience mbH
& Co. KG, owned by the majority of the investment-company of the
Hopp familiy. In this transaction, LION bioscience AG will pay in
shares using the authorized capital of the company. Furthermore, as
both investment companies of the Hopp family committed further

capital inflow into LION bioscience AG, it is to be expected that they will
further increase their stake in LION.
For further information, please contact:
|Peter Willinger |Dr. Franz-Werner Haas |
|Chief Executive Officer |General Counsel |
|Tel: +49 (0) 6221-4038 293 |Tel: +49 (0) 6221-4038 340 |
|Email: |Email: |
|peter.willinger@lionbioscience.com |franz.werner.haas@lionbioscience.c|
| |om |
| | |
###
Except for the historical information contained herein, the matters set forth
in this press release are forward looking. These forward-looking statements may
include projections, assumptions, estimates, targets, and descriptions of
future events. Such statements are based on currently available information and
on LION's current expectations as to future events that may not prove to be
accurate. These statements are not guarantees of future performance and involve

risks and uncertainties that are difficult to predict. Many factors
could cause the actual results, performance or achievements of
LION to be materially different from those that may be projected,
expected, targeted, expressed or implied by such statements. All
roll-out plans and future dates with respect to completion of
development and market release of LION products are target dates
only based on the company's current planning and may change in the
future. Any delays in the current product release schedule will have
a materially adverse effect on the company's targets for fiscal
year. ###

end of announcement euro adhoc 05.07.2006 21:40:19
--------------------------------------------------------------------------------

ots Originaltext: Lion Bioscience
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Stephan Trautvetter
Director Finance & Accounting
Telefon: +49(0)6221 4038 476
E-Mail: stephan.trautvetter@lionbioscience.com

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
New York / ADR
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade